Communiqués Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
3,65 ^USD	-7,59 %		+20,07 %	-15,70 %

02/06	Puma Biotechnology, Inc. annonce la présentation des résultats d'une étude de phase II sur l'alisertib dans le cancer du sein métastatique résistant à l'endocrinien (Tbcrc 041)	CI
17/05	Pfizer obtient 107,5 millions de dollars d'AstraZeneca dans un procès sur les brevets de médicaments anticancéreux aux États-Unis	RE

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	02/07	BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	07/06	BU
Puma Biotechnology : Corporate Presentation	03/06	PU
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer	03/06	BU
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)	02/06	BU
Puma Biotechnology to Join Russell 3000 Index	28/05	BU
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting	23/05	BU
Puma Biotech: Q1 Earnings Snapshot	02/05	AQ
Puma Biotechnology Reports First Quarter Financial Results	02/05	BU
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	18/04	BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	04/04	AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	03/04	BU
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03	BU
Puma Biotechnology : Corporate Presentation	06/03	PU
Puma Biotech: Q4 Earnings Snapshot	29/02	AQ
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	29/02	BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	28/02	BU
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	22/02	BU
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	15/02	BU
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Communiqués

Filtres